{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-022876","form_type":"8-K","ticker":null,"cik":"0001694665","company_name":"Evelo Biosciences, Inc.","filed_at":"2023-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.176093+00:00","generated_at":"2026-06-20T02:29:33.494856+00:00","sec_items":["2.05","5.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Evelo Biosciences cuts 45% workforce; Phase 2 atopic dermatitis trial fails primary endpoint","bullets":["Workforce reduction of 48 employees (45% of headcount); estimated $2.7M charges, cash runway extended into Q3 2023.","Phase 2 trial of EDP1815 in atopic dermatitis failed primary endpoint (EASI-50) in three cohorts due to high placebo rates; fourth cohort data expected Q2 2023.","Positive regulatory feedback from FDA, EMA, MHRA for Phase 3 plans of EDP1815 in psoriasis; clear path to global registration.","Dosing started for Phase 1 of EDP2939 (EV product) in psoriasis; Phase 2a dosing planned Q1 2023; data H2 2023.","CFO Marella Thorell appointed principal accounting officer after CAO departure; CEO search halted, Simba Gill remains."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-022876","json":"https://secwatch.observer/filing/0001193125-23-022876.json","markdown":"https://secwatch.observer/filing/0001193125-23-022876.md","text":"https://secwatch.observer/filing/0001193125-23-022876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1694665/000119312523022876/0001193125-23-022876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1694665/000119312523022876/d344481d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T02:29:33.494856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22214ffbdf","claim":"Marella Thorell was appointed as Principal Accounting Officer at Evelo Biosciences, Inc..","evidence_excerpt":"On the same date, the Board appointed Marella Thorell, the Company’s Chief Financial Officer, Senior Vice President, Treasurer and principal financial officer, as the Company’s principal accounting officer effective upon Mr. Carriere’s departure.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1694665/000119312523022876/0001193125-23-022876-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"32117b579f","claim":"Stephen J. Carriere departed as Chief Accounting Officer at Evelo Biosciences, Inc..","evidence_excerpt":"On January 31, 2023, Stephen J. Carriere, the Company’s Chief Accounting Officer, was informed that his position was being eliminated in connection with the Workforce Reduction.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1694665/000119312523022876/0001193125-23-022876-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"73eec7b9c767bce4dcd8205fef9f3e96826f4471","claim":"Evelo Biosciences, Inc. announced a restructuring with charges of aggregate charges in connection with the Workforce Reduction of approximately $2.7 million, which relate primarily to severance payments and related continuatio affecting workforce (48 employees, or approximately 45% of the Company's headcount as of January 31, 2023).","evidence_excerpt":"and prioritize investment in its core clinical programs. The Company estimates that it will incur aggregate charges in connection with the Workforce Reduction of approximately $2.7 million, which relate primarily to severance payments and related continuation of benefits costs, all of which are anticipated to result in future cash expenditures, along with the","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1694665/000119312523022876/0001193125-23-022876-index.htm","confidence":1.0,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"aggregate charges in connection with the Workforce Reduction of approximately $2.7 million, which relate primarily to severance payments and related continuatio"},{"label":"Affected area","value":"workforce"},{"label":"Headcount","value":"48 employees, or approximately 45% of the Company's headcount as of January 31, 2023"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}